Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.

ABSTRACT:

Background

PCSK9 inhibition is a new powerful cholesterol-lowering strategy. Recently, it was reported that CETP inhibitors influence PCSK9 levels as an off-target effect. We explored the relationship between circulating PCSK9 levels and CETP activity in patients with metabolic disease who were not on lipid-lowering therapy.

Methods

Plasma CETP activity and PCSK9 levels were measured in 450 participants (median age, 58 years; 49 % women) who attended the metabolism unit because of metabolic syndrome (MetS) (78 %), atherogenic dyslipidemia (32 %), obesity (50 %), type 2 diabetes mellitus (72 %), and other risk factors (13 %). A 6 week lipid-lowering drug wash-out period was established in treated patients.

Results

Both PCSK9 levels and CETP activity were higher in pati

SUBMITTER: Girona J 

PROVIDER: S-EPMC4973048 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature